HC Wainwright & Co. Maintains Buy on OKYO Pharma, Raises Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Yi Chen has reaffirmed a Buy rating on OKYO Pharma (NASDAQ:OKYO) and increased the price target from $4 to $5.
January 08, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
OKYO Pharma's Buy rating is maintained by HC Wainwright & Co., with a raised price target from $4 to $5, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and can lead to increased investor confidence, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100